News & Updates

Show Multimedia Only
Dolutegravir knocks down HIV faster than bictegravir in French study

Dolutegravir knocks down HIV faster than bictegravir in French study

06 Oct 2026 byElvira Manzano

Final analysis of the BicDol study, presented at AIDS 2026, suggests that a first-line triple antiretroviral regimen containing dolutegravir suppresses HIV more rapidly than one containing bictegravir, particularly among patients with the highest viral loads.

06 Oct 2026
Fewer major bleeds with prasugrel as default antiplatelet after PCI

Fewer major bleeds with prasugrel as default antiplatelet after PCI

04 Oct 2026 byElvira Manzano

When prasugrel is the default antiplatelet for patients with acute coronary syndromes (ACS) undergoing PCI*, fewer major bleeds occur than when ticagrelor is the default, according to the SWITCH-SWEDEHEART study presented at ESC 2026. This benefit is not accompanied by increased ischaemic events.

04 Oct 2026